Our laboratory has previously described the presence of five tumor-specific low molecular weight isoforms of cyclin E in both tumor cell lines and breast cancer patient biopsies. We have also shown that one of these low forms arises from an alternate start site, whereas the other four appear as two sets of doublets following cleavage through an elastase-like enzyme. However, the origin of both sets of doublets was unknown. Here, we demonstrate that the larger isoform of each doublet is the result of phosphorylation at a key degradation site. Through site-directed mutagenesis of different phosphorylation sites within the cyclin E protein, we discovered that phosphorylation of threonine 395 is responsible for generating the larger isoform of each doublet. Because phosphorylation of threonine 395 has been linked to the proteasome-mediated degradation of full length cyclin E, we examined the stability of T395A phospho-mutants in both non-tumorigenic mammary epithelial cells and tumor cells. The results revealed that the low molecular weight isoforms appear to be stable in both a tumor cell line and a nontumor forming cell line regardless of the presence of this critical phosphorylation site. The stability of low molecular weight cyclin E may have implications for both tumorigenesis and treatment of tumors expressing them.
Introduction
Cyclin E is a key regulatory protein for the transition of G1 to S phase of the cell cycle. Stable and/or high levels of cyclin E expression have been linked to poor prognosis in breast cancer patients (Porter et al., 1997) . Abnormally high levels of cyclin E-associated activity can cause increased genetic instability and tumorigenicity in both mice and cultured cells (Karsunky et al., 1999; Spruck et al., 1999; Minella et al., 2002; Hwang and Clurman, 2005; Loeb et al., 2005; Smith et al., 2006; Akli et al., 2007) . Another aspect of cyclin E as it relates to cancer is the appearance of low molecular weight (LMW) isoforms of cyclin E. These isoforms (from 45-33 kDa) are specific to tumor cells (Harwell et al., 2000) . Although only the 50 kDa cyclin E protein is found in normal cells, breast cancer cells have been demonstrated to express up to 5 LMW isoforms which correlate with poor patient outcome (Keyomarsi et al., 1994) . The LMW isoforms of cyclin E are produced through aberrant proteolysis of full length cyclin E by the protease elastase (Porter et al., 2001) , although there exists some evidence that the protease calpain 2 may be both upregulated by cyclin E and responsible for also producing these isoforms (Libertini et al., 2005) . However, recently a specific inhibitor of elastase indole-3-carbinol (I3C), a naturally occurring component of Brassica vegetables, was shown to induce a G(1) cell cycle arrest of human breast cancer cells by targeting the generation of the LMW isoforms of cyclin E (Nguyen et al., 2008) . Specifically, the authors show that treatment of highly invasive MDA-MB-231 breast cancer cells with I3C shifted the stable accumulation of cyclin E protein from the hyperactive LMW form to the 50-kDa form. They also use an in vitro cyclin E processing assay to demonstrate that I3C disrupts the proteolytic processing of the 50-kDa cyclin E into the LMW forms by direct inhibition of human neutrophil elastase enzymatic activity (Nguyen et al., 2008) . This study provides direct evidence that elastase uses cyclin E as a substrate to generate the LMW forms of this protein. These LMW isoforms have a greater associated kinase activity compared with the full length cyclin E protein (Wingate et al., 2003; Akli et al., 2004) . Overexpression of the LMW forms of cyclin E in a nontumorigenic mammary epithelial cell line (76NE6) with an intact G1 checkpoint demonstrated that the LMW forms caused an increase in the S-phase population and a concomitant increase in proliferation compared with overexpression of the full length cyclin E (Wingate et al., 2003) . This increase in proliferation was attributed to the increased kinase activity of the LMW cyclin E isoforms, and was shown not to be due to a lack of inhibitor binding to the LMW forms. The changes in proliferation were not exhibited in cells overexpressing the full length cyclin E. This defect in S phase led to several chromosomal abnormalities, including chromosomal breaks, fragments and fusions; the number of metaphases with polyploidy or tetraploidy was also increased (Akli et al., 2004) . This observation is consistent with the increase in polyploid nuclei seen in breast cancer tissue samples, which are positive for the LMW forms of cyclin E. The transforming potential of the cyclin E LMW forms has also been demonstrated in non-metastatic melanoma cells (Bales et al., 2005) . Overexpression of the LMW cyclin E isoforms in these cells generated invasive, angiogenic tumors, unlike cells expressing only the full length cyclin E. The LMWexpressing cells also exhibited a dramatic increase in lung metastases. The oncogenic potential of LMW cyclin E has also recently been demonstrated in vivo. Transgenic mice expressing the LMW isoforms of cyclin E in their mammary gland were susceptible to metastatic mammary carcinoma, whereas the full length overexpressing transgenic mice did not (Akli et al., 2007) . A restrospective study of 395 breast cancer patients demonstrated that overall expression of cyclin E and expression of the LMW forms of cyclin E were better prognostic indicators than nodal status (nodal status had been the best indicator up to this point) (Keyomarsi et al., 2002) . Lastly, we recently determined the specificity of LMW cyclin E to cancer cells by measuring cyclin E expression in tumor and non-tumor tissues from 340 breast cancer patients. Our results reveal the LMW isoforms were detected significantly more frequent in breast tumor tissues than in adjacent non-tumor breast tissues (Po0.0001) (Wingate et al., 2009) .
Although it is clear that the LMW forms of cyclin E can have an important part in tumor growth and metastasis, a complete understanding of their genesis is still needed. We have previously shown that the elastasemediated cleavage of full length cyclin E is sufficient to give rise to two sets of doublet LMW cyclin E we termed EL2/3 and EL5/6. However, as only two elastase cleavage sites generated four different LMW cyclin E, it posed the question whether each of the doublets were the result of post-translational modification. Uncovering the mechanism by which all the LMW isoforms are created and elucidating their function is the purpose of our study here.
Results
Low molecular weight forms of cyclin E seen in tumor cells at 45 and 35 kDa are due to phosphorylation of elastase-cleaved 44 and 33 kDa cyclin E The low molecular weight forms of cyclin E observed in tumor cells are formed by elastase cleavage of full length cyclin E (producing EL2/3, and EL5/6; see Figure 1a ). EL4 is formed by an alternative start site at methionine 46 and is found mainly in tumor cells; however, normal cells can also generate this form. The origin of the EL2/3 and EL5/6 doublets is not currently known. Cyclin E is post-translationally modified by phosphorylation on at least seven known sites: serines 73, 90, 103, 387 and 399 and threonines 77 and 395. Cyclin E was originally thought to be a 396 amino acid protein; however, mass spectrometry analysis of cyclin E in our laboratory has demonstrated that the predominant form of cyclin E found in both normal and tumor cell lines is indeed 15 amino acids longer on the amino terminus (mass spectrometry of tryptic peptides demonstrated the presence of an internal 16 methionine at position 16) (Porter et al., 2001 Figure 1 (a) Schematic of full length (51 kDa) and low molecular weight forms (LMW) of cyclin E in breast tumor cell line MDA-MB-436. Expression constructs give rise to all six isoforms (pcDNA 3.1 cyclin EL), isoforms EL2-EL6 (pcDNA 3.1 cyclin E Trunk 1) or isoforms EL5 and EL6 (pcDNA 3.1 cyclin E Trunk 2). The * denotes the sites that are phosphorylated at T395. The lane presented is the western blot analysis of whole cell lysates from MDA-MB-436 cell line. (b) Phosphatase treatment alters the banding pattern of the LMW forms. Western blot analysis of cyclin E in MDA-MB-436 cells with or without protein phosphatase 1 (PP1) treatment. The EL2/3 doublet at 45/55 kDa is resolved to a single band following phosphatases treatment (right lane). Similarly, the EL5/6 doublet at 35/33 kDa is reduced to a single isoform upon dephosphorylation. The level of EL1 (full length cyclin E) is not altered by the phosphastase.
Phosphorylation of low molecular weight cyclin E BB Mull et al previous studies will be altered here to reflect this data; that is, residue T62 will be referred to in this work as T77 and residue T380 as T395. Of these, only T77, S103, S387 and T395 have been shown to be phosphorylated in vivo, and of those T77 and T395 are crucial for degradation through ubiquitination and the proteasome (Clurman et al., 1996; Won and Reed, 1996; Welcker et al., 2003) . We hypothesized that the doublets seen at 45/44 and 35/33 kDa are due to phosphorylation on one or more of the known phosphorylation sites of cyclin E. To better understand the origins of the low molecular weight doublets, we asked if treatment with phosphatase could alter the mobility of these bands. MBA-MB-436 cell line (see Figure 1b) were treated with protein phosphatase 1; treated cell lysates were subjected to western blot analysis, and a shift was seen in the LMW isoforms of cyclin E, but no change in the full length was observed ( Figure 1b) . Specifically, the doublet at EL 2/3 resolved to a single band, as did the EL 5/6 doublet. The intensity of EL4 was also diminished following phosphatase treatment. As phosphatase treatment of cell extracts could have many indirect effects, such as altering the activity of a pre-existing protease, we also examined this question in the context of just EL2/3. To this end, we transfected MDA-MB-436 cells with a Flagtagged cyclin E construct that codes for EL2/3 (that is, Trunk 1). Twenty-four hours post-transfection, cells were harvested and subjected to immunoprecipitation with an antibody to FLAG, resolved electrophoretically and the SeeBand stained bands corresponding to Trunk 1 were excised, eluted from the gel and treated with protein phosphatase 1. The treated cell lysates were then subjected to western blot analysis with cyclin E, and a shift was seen in the LMW isoforms of cyclin E, as compared with the untreated cell lysates (Supplementary Figure 1) . Specifically, the doublet at EL 2/3 resolved to a single band. The results from both these complimentary experiments suggested that phosphorylation has a role in the appearance of the LMW isoforms, but exactly how was still unclear. To identify the phosphorylation sites within cyclin E that would be responsible for generation of the EL2/3 and EL5/6 doublets, phospho-mutants of cyclin E were created through site-directed mutagenesis. To this end, threonines 77 and 395 (the only two sites implicated in cyclin E stability) (Clurman et al., 1996; Won and Reed, 1996; Welcker et al., 2003) were changed to alanine in expression plasmid constructs for three different plasmids; (i) full length cyclin E (pcDNA 3.1 EL) and (ii-iii) which mimic the elastase-derived low forms, named Trunk1 and Trunk 2 (see Figure 1a) . Each of these three cyclin E constructs was mutated at threonine 77 (termed 77), threonine 395 (termed 395) or both sites in tandem The location of these sites for each cyclin E isoform is shown in Figure 2a . To examine the protein products of these vectors, each of the 12 constructs was transfected into 293T cells; exogenous cyclin E was immunoprecipitated with anti-FLAG (all cyclin E constructs are FLAG tagged) and analysed through western blotting with cyclin E. As seen in Figure 2b , mutation at threonine 395 abolished both the EL2 and EL5 forms (*indicate phosphorylation products for T395A for each isoform); modification of threonine 77 had no effect, and the double mutant constructs mirrored the T395-A constructs (data not shown). The 293T cells have very high levels of elastase and the elastase-mediated cleavage of each transfected isoform is also detected in each lane. To examine the shift in molecular weight of T395A LMW in a cell line that has low levels of elastase, we repeated this experiment in MDA-MB-436 cells. The results revealed that transfection of cells with T395A constructs shifted the molecular weight of bands corresponding to EL2 and EL5. Therefore, the low molecular weight isoforms of cyclin E at 45 kDa (EL2) and 35 kDa (EL5) are the T395-phosphorylated forms of EL3 and EL6, respectively. These results suggest that the LMW forms of cyclin E are generated as a result of elastase-mediated cleavage of full length cyclin E (as apparent in 293T cells) and by phosphorylation at the threonine 395 (in both 293T and MDA-MB-436 cells). As both phosphorylated and unphosphorylated species of the LMW cyclin E are generated in tumor cells, next we set out to examine the activity of these forms in both normal and tumor cells.
Mutation of threonines 395 and 77 to alanine in cyclin E does not alter its associated kinase activity or modify the binding of its protein partners Although the sites (T395 and T77) mutated for this study lie outside the region for protein partner binding (cyclin box), it was important to ensure that these changes do not alter the kinase activity or the binding of kinases and kinase inhibitors to cyclin E. The hypothesis to be tested in this series of experiments is that mutation of threonines 395 and/or 77 does not alter the expression or binding of cdk2, p21 or p27, and that the cyclin Eassociated kinase activity is similarly unaffected. To this end, the constructs detailed above were again transfected into 293T and 76NE6 mammary epithelial cell lines. Western blot analysis of the transfectants demonstrates a constitutive expression level of cdk2 and p27 across all expression construct backgrounds in both cell lines (Supplementary Figure 2) . Exogenous Cyclin E was immunoprecipitated from the 293T cell extracts with an anti-FLAG antibody and subjected to a histone H1 kinase assay. As seen in Figure 3 , no alterations in activity were observed with any of the mutations to cyclin E. Densitometric values are the average of three samples per construct and reveal a similar level of activity among the wild-type and phospho-mutant constructs. The kinase analysis was also done in a normal-derived mammary cell line, 76NE6. Densitometry was performed on the kinase assay samples (three per construct); as seen in Figure 3 , no changes in activity were observed for the 76NE6 cell lines in any mutant construct. It is possible that any alterations in activity could be masked by saturation of endogenous cdk2 by the overexpressed cyclin E constructs. To rule out this possibility, the kinase assay was performed on wild-type and double mutant cyclin E immunoprecipitates supplemented with excess cdk2 produced in SF9 cells. As before, the mutation of the phosphorylation sites does not alter the kinase activity of the associated cdk2 (Supplementary Figure 3) . These results are consistent with previous studies (Clurman et al., 1996) , which 
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Figure 2 (a) Schematic of known cyclin E sites of phosphorylation. The sites T395 and T77 were mutated singly and in tandem for the full length (cyclin EL) and LMW (Trunk1 and Trunk2) cyclin E constructs. (b) T395A mutation inhibits the generation of EL2 and EL5. FLAG immunoprecipitation of full length (EL) and LMW (Trunk1 and Trunk2) cyclin E wild type (wt) and phospho-mutant construct (see a). 395 ¼ T395A. The first lane depicts the pattern of full length cyclin E and its LMW forms (EL-1 to EL-6) expressed endogenously in MDA-MB-157 cells, which naturally overexpress cyclin E. 293T and MDA-MB-436 cells were transfected with the wild type (wt) and T395A (395) variants of the indicated EL, T1 and T2 constructs, subjected to IP with FLAG and immunoblotting with cyclin E. Within each set of constructs (EL, Trunk1 or Trunk2) the loss of the T395 phosphorylation site results in the loss of the EL2/3 and EL5/6 doublets. The red * indicates the position of the missing bands in the T395A EL, T1 and T2 constructs in the 293T cell line. This pattern is repeated in the Trunk1 and Trunk2 constructs, as well as in the breast tumor cell line MDA-MB-436. Figure 3 Changes in phosphorylation status of LMW cyclin E does not alter their activity in normal or tumor cells. Histone H1 kinase assay of cyclin EL full length and LMW constructs in 293T cells; wt ¼ wild type, 395 ¼ T395A, 77 ¼ T77A, d ¼ T395/77A. Exogenous cyclin E was immunoprecipitated FLAG and subjected to kinase assay. A representative sample set is shown in the top panel. Densitometry for each of the constructs (Cyclin EL, Trunk1 and Trunk2 and mutants) indicates no significant alteration in the associated kinase activity. Each condition was assayed three times and percent activity normalized to wild type for each parental construct. Error bars are ± s.e.m.
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showed that the associated kinase activity of five different phospho-mutant constructs of full length cyclin E are similar to that of wild-type cyclin E.
To assess any changes in binding of cyclin E/cdk2 partners due to the mutations, immune complexes of phospho-mutant cyclin E were next examined. Wildtype and double-phospho-mutant constructs were transfected into 293T cells and immunoprecipitated using anti-FLAG and immunoblotted to detect cdk2 and p27. Western blot analysis for cdk2 and the inhibitor p27 demonstrates no alterations in binding in the mutant cyclin E constructs as the level of binding of cdk2 and p27 were very similar in cells transfected with wild-type versus the phospho-mutant constructs (Figure 4a) . The analysis was then repeated in 76NE6 cells to assess if the behavior of the aforementioned constructs would be any different in a non-tumorigenic cell line ( Figure 4b ). As before, no changes were seen in the protein-binding ability of the cyclin E phospho-mutants to cdk2 or p27. Therefore, although the mutation at threonine 395 prevents its phosphorylation and the generation of EL2 and EL5 isoforms, neither that site nor T77 appear to be involved in the associated kinase activity or its ability to bind regulatory p27 or kinase partner cdk2.
Low molecular weight isoforms of cyclin E are more stable than the full length cyclin E in both normal-and tumor-derived cell lines The phosphorylation of cyclin E at T395 (and to a lesser extent T77) is crucial to its degradation through the ubiquitin/proteasome pathway (Strohmaier et al., 2001; Welcker et al., 2003; Ye et al., 2004) . It has already been demonstrated by others (Clurman et al., 1996; Welcker et al., 2003) that mutation of either T395 or both T395 along with T77 severely inhibits the degradation of full length cyclin E. However, the role of these sites in the stability of the LMW forms of cyclin E has not yet been established. To evaluate the putative roles of these sites, we transfected the full length cyclin E (EL) and its double mutant form (Ed) into 293T cells. After 24 h, the cells were treated with cycloheximide to prevent further protein synthesis. Cells were harvested at 0, 100 and 200 min following cycloheximide treatment, and the status of cyclin E was analysed by western blotting. As expected, the wild-type cyclin E degraded over time whereas the mutant form was stable (wild-type Figure 5 , mutant data in Supplementary Figure 4) . The same analysis was performed following transfection of the cyclin E LMW constructs Trunk 1 and Trunk 2 and their T395/77-A double mutants. Although the stability of the double mutant forms was expected (Supplementary Figure 4 ) the resistance of wild-type LMW cyclin E to degradation was a novel finding. As seen in Figure 5 , the same analysis in the normal-derived 76NE6 cell line produced a similar result. Full length wild-type cyclin E was degraded over the 200 min time period, whereas the T395/77-A phospho-mutant remained stable. However, both the Trunk 1 and Trunk 2 LMW cyclin E constructs were stable, even though the phosphodegron sites T395 and T77 had not been altered ( Figure 5 ). To ensure that the length of the experiment is not masking any potential degradation at a later time point, we treated the cells with cycloheximide for 400 min (Supplementary Figure 4A) . As before, the full length wild-type cyclin E was degraded with similar kinetics as that of the 200 min experiment, whereas all the other isoforms and their phospho-mutant products remained stabile. These results suggest that when full length cyclin E is modified to generate the LMW forms of cyclin E, a tumor-specific event, that these LMW forms are now more stable. One possible explanation for this phenomenon may be differential cellular localization. As demonstrated in a recent study from our laboratory, the LMW cyclin E isoforms localize almost exclusively in the cytoplasm; full length cyclin E was found in both nuclear and cytosolic fractions (Delk et al., 2009) . The ubiquitin ligases responsible for cyclin E degradation, Fbw7a and Fbw7g, are localized in the nucleus. As LMW cyclin E is sequestered apart from the ligases, it may be stabilized. Based on these results, we next asked if the localization of the double mutants of each of the constructs is also altered. To this end, 293T cells were transfected with either the wild-type or the double phospho-mutant constructs. Forty-eight hours post-transfection, cells were harvested and subjected to fractionation and western blot analysis as described (Delk et al., 2009) . As seen in Figure 6 , although full length cyclin E (wild-type and its phospho-mutant analog) is found in both the nuclear and cytoplasmic fractions, both the LMW isoforms and their phosphomutant variants were exclusively cytoplasmic and as such are able to escape nuclear-mediated degradation.
Discussion
The work entailed here began with attempting to answer how all the low molecular weight (LMW) forms of cyclin E are generated in tumor cells. The action of elastase has been described as generating the forms EL2, EL3 and EL5 and EL6. An alternate start site at methionine 46 results in EL4. The question still unanswered was still how the EL2/3 and EL5/6 doublets are generated. An established post-translational modification of cyclin E is phosphorylation, so this was targeted as the leading possibility. By phosphatase treatment of breast tumors cells as well as transfection of cyclin E phospho-mutants, it was discovered that phosphorylation at site T395 gives rise to both EL2 and EL5. Mutations lacking this phosphorylation site only produce EL1, EL3, EL4 and EL6. It should also be noted that this finding is in conflict with a report in the literature which stipulates that cyclin E must first have a 'priming' phoshoryl group at T77 before the phosphorylation event at T395 (Ye et al., 2004) . As the T77A mutant construct was efficiently phosphorylated to give EL2 and EL 5, just as in the wild type, this pathway must not hold true for the LMW forms of cyclin E.
Because the T395 site is critical for proper degradation of the cyclin E bound to cdk2 at the end of S phase, it was questioned whether or not these low forms of cyclin E would behave similarly. To use the mutated constructs as a model system, they would first be evaluated for proper kinase activity. Transfections in 293T cells, a breast cancer cell line (MDA-MB-436) as well as a normal-derived, non-tumorigenic breast epithelial cell line, 76NE6 all proved to be consistent regarding cyclin E-associated cdk2 kinase activity. Neither the T395A mutation nor the T77A hindered the associated kinase activity; the double mutant was active as well. It was also noted that overxpression of these transgenes did not alter the associated kinase (cdk2) or the inhibitors p21 and p27. Therefore, we felt justified in using the phospho-mutant constructs as our model system to analyse the degradation of cyclin E LMW forms.
Cyclin E bound to cdk2 is degraded via the ubiquitin/ proteasome pathway following phosphorylation on (at After a 24 h transfection, cells were treated for 0, 100 or 200 min with cycloheximide to prevent further protein synthesis. The levels of protein were analyzed via western blotting in (a). In both cell lines, full length wild-type cyclin E (EL) was degraded over the time course of the cycloheximide treatment. Double mutant full length (Ed) was stable, as the phosphorylation sites needed for degradation were not present (data not shown). In both cell lines, the LMW cyclin E constructs (Trunk1 and Trunk2) were stable over the cycloheximide treatment course, even though the phosphodegron sites T395 and T77 were present. Phospho-mutant Trunk1 and Trunk2 were also stable (data not shown). Each time point was done in triplicate. Densitometric analysis of cyclin E levels as a percentage of time zero appears in (b). LMW cyclin E wild-type and phosho-mutant variants are cytoplasmic. 293T cells were transfected with the indicated constructs and 24 h following transfection, cells were subjected to nuclear and cytoplasmic fractionation and subjected to western blot analysis with antibodies to cyclin E, anti-parp (nuclear specific) and anti-grb-2 (cytoplasm specific).
EL
least) threonine 395. Transfection of wild-type full length cyclin E, along with cdk2, resulted in the expected pattern of degradation following cycloheximide treatment. The T395/77A double mutant was stabilized, which also follows the reports in the literature for in vitro and in vivo systems (Minella et al., 2008) . However, transfection of the LMW forms (wild-type and phospho-mutant) gave a stable cyclin E protein, regardless of phospho-site status. It is possible that these LMW forms can evade the normal Fbw7-ubiquitin-proteasome degradation pathway. A recent report detailing the importance of nearby modified sites in the dimerization of Fbw7 upon binding to cyclin E raises the possibility that the LMW forms interfere with this process (Welcker and Clurman, 2007) . Another report from our laboratory (Delk et al., 2009 ) further demonstrates that LMW cyclin E is predominantly located in the cytoplasm, whereas full length cyclin E is nuclear. This differential sequestration of LMW cyclin E may allow it to evade degradation by Fbw7a and Fbw7g, which are also nuclear-localized. This altered localization also occurs with the mutated LMW cyclin E isoforms analysed in this study. Future work in this area would evaluate the binding of the Fbw7 proteins, the Pin1 isomerase and the nuclear localization of the cyclin E LMW forms to better understand their degradative pathway. The hyperactivity and resistance to the CIP/KIP inhibitors of cyclin E LMW isoforms has been previously determined, as has their value as a prognostic indicator in breast cancer patients. The finding here that they are also more stable than the full length form of cyclin E also may have clinical implications. Our results demonstrate that the LMW cyclin E isoforms are phosphorylated on the key degradative-signaling site (T395); the loss of forms EL2 and EL5 upon its mutation clearly indicates phosphorylation. However, the ability to be phosphorylated at this site does not seem to be sufficient to start the degradative process of the LMW cyclin E isoforms. Two possibilities exist for this stability; either Fbw7 is unable to bind phospho-T395 LMW cyclin E, or it does bind but is unable to complete the ubiquitination process. Both 76NE6 and 293T cell lines have functional Fbw7, and the full length cyclin E is properly degraded in both settings. The exact mechanism of this stability will be the focus of further study. Although mutations and other Fbw7 aberrances have been linked to several different tumor types (Welcker, 2008, review) , the LMW isoforms of cyclin E seem to be stable even in the presence of functional ubiquitin ligation and proteasomal degradation. This is important clinically; prognostically, the status of Fbw7 in a tumor-expressing LMW cyclin E will unlikely be of significant consequence. These stable isoforms will then be able to enhance the tumorigenicity of the cancer, increasing both cell division and genetic abnormalities. While much is known about the activity and prognostic value of LMW cyclin E, specifically targeting them as a means of therapy has proven difficult. Broad spectrum kinase inhibitors affect other complexes to a greater extent than LMW cyclin E/cdk2, and an antibody which binds only the LMW isoforms (but not the full length) is as yet unavailable. Targeting elastase may be an alternative way to inhibit the generation of the LMW forms of cyclin E. When the crystal structure of cyclin E was resolved in 2005, it was noted that the amino terminus of cyclin E could not be crystallized. It is this amino terminus that differentiates full length from the LMW forms of cyclin E. The authors used elastase to cleave cyclin E into its LMW forms, which was then able to be crystallized (Honda et al., 2005) . Development of a method for targeting these LMW isoforms specifically (either through inhibition of their activity or through inhibition of elastase) would be of great clinical value. .035 mg/ml bovine pituitary extract, 0.01 mM ascorbic acid, 0.2 nM b-estradiol, 2.5 ng/ml sodium selenite, 0.01 mg/ml transferrin, 12.5 mg/ml estrogen growth factor and 0.01 mg/ml ciprofloxacin. Cells were split upon reaching 70% confluency by treatment with 0.25% trypsin (Gibco/Invitrogen Carlsbad, CA, USA) for 5 min at 371. Trypsin is neutralized by addition of media with 10% FCS.
Materials and methods
Cell lines
Transfections
Two different transfection protocols were used in this study. Transfections with FuGENE (Roche Diagnostics, Basel, Switzerland) are done as follows: 18 ml FuGENE is added to 600 ml serum-free media, mixed gently and is allowed to sit for 5 min. Plasmid DNA (6 mg) is added to the mixture, and is further incubated for 20 min. The mixture is then added to cells (70% confluent) in a 100 mm dish. Transfections with GeneJuice (Novagen/EMD Biosciences, San Diego, CA, USA) are as follows. GeneJuice (15 ml) is added to 500 ml serum-free media, which is gently mixed and allowed to stand for 5 min. Plasmid DNA (15 mg) is added to the mixture, which then incubates for an additional 20 min. The mixture is then added to cells (70% confluent) growing in a 100-mm dish. GeneJuice was utilized for the cycloheximide experiments; FuGENE was used for all other experiments.
Cell harvesting/protein extraction Twenty-four hours after transfection, cells are harvested for protein extraction. Cells are trypsinized (see cell lines above) and treated with media containing 10% fetal calf serum. Cells are collected into 50 ml conical tubes and washed with 20 ml cold phosphate-buffered saline (PBS). Cells are centrifuged at 280 g for 5 min at 4 1C. The wash is discarded, and a second wash with 20 ml PBS is done. Cells are resuspended in a minimum (40-50 ml) of protease/phosphatase inhibition buffer: 25 mg/ml leupeptin, 25 mg/ml aprotinin, 10 mg/ml pepstatin, 1 mM benzamidine, 10 mg/ml soybean trypsin inhibitor, 0.5 mM PMSF (Phenyl methyl sulfonyl fluoride), 50 mM sodium fluoride, 0.5 mM sodium orthovanadate. Cells are lysed by two rounds of sonication (one round ¼ 3 min sonication, 1 min rest, 3 min sonication) and are vortexed between rounds. Sonication is performed in an ice/water bath by a Sonicator XL (Misonix Inc., Farmingdale, NY, USA). The protein suspension is then separated by centrifugation at 125 000 g for 45 min at 4 1C. The protein suspension is stored at À80 1C.
Western blot analysis
Western blot protein analysis is done as previously described (Porter et al., 2001) . Briefly, samples are boiled in denaturing sample buffer and are run at 150 V for 90-120 min, depending on the location of the proteins of interest. Following electrophoresis, the gels are transferred to polyvinylidene fluoride membranes. The primary antibodies used are: anticyclin E (0.3 mg/ml), anti-cdk2 (1.0 mg/ml)-both from SantaCruz (Santa Cruz, CA, USA). Anti-cyclin E is HE12, catalog number SC-247. Anti-p21 is 1.0 mg/ml from Calbiochem (EMD, Gibbstown, NJ, USA). Anti-p27 (1.0 mg/ml) is from BD TransLab (San Jose, CA, USA). Anti-FLAG (M2, 10 mg/ ml) is from SigmaAldrich (St Louis, MO, USA). All primary antibodies are monoclonal.
Immunoprecipitation/kinase assays IP kinase and western blot analyses are done as previously described (Porter et al., 2001) . Briefly, protein samples are collected as above. For immunoprecipitation, protein g sepharose beads (GE HealthCare, Piscataway, NJ, USA) are washed in a lysis/protease/phosphatase buffer, 50 mM sodium fluoride, 0.5 mM sodium orthovanadate. The buffer is added to the beads at a 2:1 ratio, mixed and then centrifuged at 4 1C for 5 min at 1000 g. This wash is carried out three times. After the wash buffer is removed, the beads (30 ml per sample) are added to a 10 mM DTT/lysis buffer (36 ml per sample). Anti-FLAG antibody (1 ml per sample) is added to the mixture, and the beads plus antibody are left to rotate slowly at 4 1C overnight. The following day, 150 mg of protein sample is added to each mixture and allowed to mix at 4 1C for 1 hour. For the titration kinase, 50 or 100 mg of cdk2-infected SF9 cell lysate was added to the mixture for 30 min before the wash step (Wingate et al., 2005) . The beads are then washed in 250 ml of the lysis/ protease/phosphatase buffer four times. For western blot analysis of the immunoprecipitated samples, beads are spun down at 2000 g for 5 min at 4 1C. All supernatants are aspirated off (beads are 'dry') and the samples are resuspended in 30 ml of a 1:1 mixture of sample buffer and PBS. Samples are then processed by the same method for western blot analysis. For a kinase assay, the same protocol is followed up to and including the four washes in PPI. However, that is followed by 4 washes in H1 buffer (10 mM MgCl 2 , 1 mM DTT, 0.1 mg/ml BSA, 25 mM Tris HCL pH 7.5, 125 mM NaCl). Following the washes, the beads are 'dried' as for the IP western. The beads are then resuspended in the kinase reaction buffer: 10 mM MgCl 2 , 1 mM DTT, 0.1 mg/ml BSA, 25 mM Tris HCL pH 7.5, 125 mM NaCl plus 60 mM ATP, 5 mCi of g-32 P ATP and 5 mg of histone H1 substrate (Roche Diagnostics). The reaction proceeds for 30 min at 37 1C. The reaction is inactivated by an addition of 15 ml of sample buffer. The samples are separated on a 13% SDS-PAGE gel. The gel is stained in Brilliant Blue (Sigma, St Louis, MO, USA) overnight. The next day, the gel is destained and dried onto filter paper. The dried gel is quantitated by exposure to a phosphorimager screen and analysis by a Typhoon scanner (GE Healthcare, Piscataway, NJ, USA). Briefly, quatitation of volume of signal is calculated using the ImageQuant software (GE Healthcare); equal-sized rectangular selection of the histone H1 signal bands are used for quantitation of the signal volume. A samesized selection of background is also selected and subtracted from the calculation for each sample.
Phosphatase treatment
Fifty micrograms of cell extract (MDA-MB-436) was used in all reactions. All enzymes were obtained from New England Biolabs (Ipswich, MA, USA). MDA-MB-436 cell extracts were incubated with 1.25 units of protein phosphatase 1 (PP1) that was used in a reaction buffer of 50 mM HEPES, 100 mM NaCl, 2 mM Dithiothreitol, 0.1 mM EGTA, 0.025% Tween 20 supplemented with 1 mM MnCl 2 and 5 mM caffeine and the reactions were incubated for 30 min at 30 1C.
Cyclin E gel extraction/phosphatase treatment The T1 cyclin E construct was transfected into 293T cells, which were harvested as before at 24 h. Exogenous cyclin E was immunoprecipitated from 450 mg of lysate using anti-FLAG (see immunoprecipitation/kinase assays above). IP-captured T1 cyclin E was separated using a 10 SDS-PAGE gel. The gel was washed three times for 10 min in ddH 2 O to remove SDS, and then stained with the SeeBand Protein Stain (GeBA, Kfar-Hanagid, Israel) for 4 h. The cyclin E T1 protein visualized by the stain was excised from the gel, and electroeluted using the GeBAflex-tube dialysis and extraction kit (GeBA). The protein was concentrated using 10% trichloroacetic acid for 1 h at 4 1C, followed by centrifugation at 20 000 g for 30 min at 4 1C. The pelleted protein was washed with cold acetone and stored at À20 1C overnight. The protein was again pelleted by centrifugation at 20 000 g for 1 h at 4 1C. The acetone was removed and the pellet briefly airdried (about 5 min). The protein was resuspended in ddH 2 O and immediately digested using protein phosphatase-1 (PP1, NEB). Protein phosphatase 1 (1.25 U) was used in a reaction buffer of 50 mM HEPES, 100 mM NaCl, 2 mM Dithiothreitol, 0.1 mM EGTA, 0.025% Tween 20 supplemented with 1 mM MnCl 2 and 5 mM caffeine. Reactions were incubated for 240 min at 30 1C. The samples were then subjected to SDS-PAGE followed by western blot analysis with cyclin E.
Plasmids
Cyclin EL, cyclin E Trunk 1 and cyclin E Trunk 2 constructs are described previously (Harwell et al., 2000) . Briefly, the FLAG epitope (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) was fused to the carboxy terminus of each cyclin E construct by PCR (5 0 EL primer: 5-GAGCGGGACACCATGC-CGAGG GAGCGCAGG-3; 5 0 Trunk 1 primer: GAGCGGGACACCA TGGATCCAGAT-GAAGAA-3; 5 0 Trunk 2 primer: GAGCG GGACACCATGGCAGTCTGTGCAGAC-3; FLAG 3 0 primer: GCAAGCTTTTCACTTGTCATCGTCGTCCTTGTA GTCCGCCATTTCCGGCCCGCT). Each cyclin E-FLAG construct was then cloned into the EcoRI site of pcDNA 3.1 (Invitrogen, Carlsbad, CA, USA).
Site-directed mutagenesis
Threonine 395 and threonine 77 were mutated to alanine by site-directed mutagenesis using the Stratagene QuikChange mutagenesis kit (La Jolla, CA, USA). The reactions used 100 ng of each primer and 50 ng of plasmid DNA in a total volume of 50 ml. The primers for mutation of T395 are: PCR products were then digested with DpnI to removed methylated (parental) DNA. Mutated DNA was transformed into XL10-gold ultracompetent cells (Stratagene). Transformations were plated LB-ampicillin plates, and colonies picked for sequencing. Primers for the T395A mutation were: 484-ATGGCGACACAAGAAAATGTTGTA and 784-CAG ATTGCAGAGCTGTTGGATCTC. The primer to validate the T77A mutation was L1cycE; GGGATGCCAAGGAGC GGGACG.
Cycloheximide treatment
After a 24 h transfection, cells were treated with cycloheximide (100 mg/ml). Transfection media was removed, and cycloheximide-treated media put on (cycloheximide in DMEM for 293T cells, in D-media for 76NE6). After the appropriate incubation time (0, 100, 200 or 400 min), the cells were harvested and processed for western blot analysis.
Cellular fractionation
After a 24 h transfection, cells were pelleted in PBS and resuspended in cold buffer A (20 mM HEPES pH 7.9, 10 mM KCl, 2.5 mM MgCl 2 , 1 mM EDTA, 1 mM DTT. 0.2% NP-40 and protease inhibitors) and held on ice for 5 min. The cells were centrifuged at 20 000 g for 60 s at 4 1C. The cytosolic supernatant was removed and analysed by western blotting. The pellet was washed two times in buffer A and then resuspended in cold buffer B (buffer A plus 20% glycerol and 20 mM NaCl) and held on ice for 30 min. The mixture was centrifuged at 20 000 g for 20 min at 4 1C. The nuclear supernatant was removed and analysed by western blotting. Anti-parp was used to indicate the nuclear fraction, and antigrb2 was used to identify the cytosolic fraction.
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